Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dimethyl fumarate immune regulation study in relapsing-remitting multiple sclerosis
NL-OMON41017Phase 4Recruiting
- Sponsor
- Orbis Medisch Centrum
- Start
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of dimethyl fumarate in multiple sclerosis (MS), sponsored by Orbis Medisch Centrum. Primary endpoints: Treg suppressive function, Treg numbers and 1 more. Started Dec 2014; status: recruiting.
02
Drugs
dimethyl fumarate
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NL-OMON41017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41017.